Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function

Neuromuscular Disorders

Volumn 24, Issue 7, 2014, Pages 583-595

  Ermolova, N V ^a,b   Martinez, L ^a,b   Vetrone, S A ^a,b,e   Jordan, M C ^a   Roos, K P ^a   Sweeney, H L ^c,d   Spencer, M J ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Paul Wellstone Muscular Dystrophy Center   (United States)

^e WHITTIER COLLEGE   (United States)

Author keywords

AKT; Inflammation; Mdx mouse; Muscular dystrophy; Myostatin; Signaling; Treatment

Indexed keywords

ETANERCEPT; INFLIXIMAB; MESSENGER RNA; MYOSTATIN; PROTEIN KINASE B; THREONINE; MONOCLONAL ANTIBODY; MSTN PROTEIN, MOUSE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DIAPHRAGM; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ENZYME PHOSPHORYLATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HISTOLOGY; LONG TERM CARE; LOW DRUG DOSE; MALE; MOUSE; MUSCLE STRENGTH; MYOFIBROSIS; NONHUMAN; OUTCOME ASSESSMENT; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; AGE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FIBROSIS; HEART; HEART MUSCLE; METABOLISM; MUSCULAR DYSTROPHY, ANIMAL; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TIME; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

AGE FACTORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; DIAPHRAGM; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; HEART; MICE, INBRED MDX; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MYOCARDIUM; MYOSTATIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901997424     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2014.04.006     Document Type: Article

References (40)

1. Spencer M.J., Montecino-Rodriguez E., Dorshkind K., Tidball J.G. Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol 2001, 98:235-243.
2. Grounds M.D., Torrisi J. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 2004, 18:676-682.
3. Hodgetts S., Radley H., Davies M., Grounds M.D. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with etanercept in mdx mice. Neuromuscul Disord 2006, 16:591-602.
4. Messina S., Vita G.L., Aguennouz M., et al. Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age. Acta Myol 2011, 30:16-23.
5. Vetrone S.A., Montecino-Rodriguez E., Kudryashova E., et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 2009, 119:1583-1594.
6. Liu J., Marino M.W., Wong G., et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998, 4:78-83.
7. Selmaj K.W., Raine C.S. Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 1995, 45:S44-49.
8. Selmaj K., Papierz W., Glabinski A., Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 1995, 56:135-141.
9. Ruddle N.H., Bergman C.M., McGrath K.M., et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990, 172:1193-1200.
10. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465.
11. Reinhart K., Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001, 29:S121-S125.
12. Spencer M.J., Marino M.W., Winckler W.M. Altered pathological progression of diaphragm and quadriceps muscle in TNF-deficient, dystrophin-deficient mice. Neuromuscul Disord 2000, 10:612-619.
13. Gosselin L.E., Barkley J.E., Spencer M.J., McCormick K.M., Farkas G.A. Ventilatory dysfunction in mdx mice: impact of tumor necrosis factor-alpha deletion. Muscle Nerve 2003, 28:336-343.
14. Radley H.G., Davies M.J., Grounds M.D. Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment. Neuromuscul Disord 2008, 18:227-238.
15. Piers A.T., Lavin T., Radley-Crabb H.G., Bakker A.J., Grounds M.D., Pinniger G.J. Blockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx and normal mice. Neuromuscul Disord 2011, 21:132-141.
16. Pierno S., Nico B., Burdi R., et al. Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach. Neuropathol Appl Neurobiol 2007, 33:344-359.
17. Chen S.E., Gerken E., Zhang Y., et al. Role of TNF-{alpha} signaling in regeneration of cardiotoxin-injured muscle. Am J Physiol Cell Physiol 2005, 289:C1179-C1187.
18. Guttridge D.C., Mayo M.W., Madrid L.V., Wang C.Y., Baldwin A.S. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000, 289:2363-2366.
19. Li Y.P., Schwartz R.J., Waddell I.D., Holloway B.R., Reid M.B. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J 1998, 12:871-880.
20. Li Y.P., Reid M.B. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1165-R1170.
21. Jordan M.C., Henderson S.A., Han T., Fishbein M.C., Philipson K.D., Roos K.P. Myocardial function with reduced expression of the sodium-calcium exchanger. J Card Fail 2010, 16:786-796.
22. Li Z.B., Kollias H.D., Wagner K.R. Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem 2008, 283:19371-19378.
23. McPherron A.C., Lawler A.M., Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997, 387:83-90.
24. Passier R., Zeng H., Frey N., et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest 2000, 105:1395-1406.
25. Haq S., Choukroun G., Lim H., et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001, 103:670-677.
26. Yang Y.J., Zhu W.L., Zhang X., Zhou X.W., Zhu Z.M. PTEN/PI3K pathways are involved in the signal transduction of myocardial remodeling in patients with congestive heart failure. Zhonghua Yi Xue Za Zhi 2005, 85:1201-1204.
27. Toker A. Newton AC: Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 2000, 275:8271-8274.
28. Monaco A.P., Kunkel L.M. Cloning of the Duchenne/Becker muscular dystrophy locus. Adv Hum Genet 1988, 17:61-98.
29. Ohlendieck K., Ervasti J.M., Snook J.B., Campbell K.P. Dystrophin-glycoprotein complex is highly enriched in isolated skeletal muscle sarcolemma. J Cell Biol 1991, 112:135-148.
30. Ohlendieck K., Campbell K.P. Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice. J Cell Biol 1991, 115:1685-1694.
31. Villalta S.A., Nguyen H.X., Deng B., Gotoh T., Tidball J.G. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 2009, 18:482-496.
32. Chen Y.W., Nagaraju K., Bakay M., et al. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 2005, 65:826-834.
33. Chu W.M. Tumor necrosis factor. Cancer Lett 2013, 328:222-225.
34. Ahn J., Kim J. Mechanisms and consequences of inflammatory signaling in the myocardium. Curr Hypertens Rep 2012, 14:510-516.
35. Kast R.E. Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities - the role of bupropion. Leuk Res 2005, 29:1459-1463.
36. Morissette M.R., Cook S.A., Foo S., et al. Myostatin regulates cardiomyocyte growth through modulation of Akt signaling. Circ Res 2006, 99:15-24.
37. Morissette M.R., Cook S.A., Buranasombati C., Rosenberg M.A., Rosenzweig A. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol 2009, 297:C1124-C1132.
38. Wagner K.R., McPherron A.C., Winik N., Lee S.J. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 2002, 52:832-836.
39. Barton E.R., Morris L., Musaro A., Rosenthal N., Sweeney H.L. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 2002, 157:137-148.
40. Kim M.H., Kay D.I., Rudra R.T., et al. Myogenic Akt signaling attenuates muscular degeneration, promotes myofiber regeneration and improves muscle function in dystrophin-deficient mdx mice. Hum Mol Genet 2011, 20:1324-1338.